Core Viewpoint - Jiangsu Yahon Pharmaceutical Technology Co., Ltd. announced the publication of clinical trial results for its product APL-1702 in the international journal "Med," which is a flagship journal in the medical field under Cell Press [2][8]. Group 1: Product and Disease Information - APL-1702 is a photodynamic therapy product that combines drug and device for the treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) [3]. - According to the 2020 Global Cancer Statistics, there were 604,127 new cases of cervical cancer globally, with 341,831 deaths, making it the fourth most common malignancy among women [3]. - In China, cervical cancer ranks second among female malignancies, with 150,700 new cases and 55,700 deaths reported in 2022 [3]. Group 2: Clinical Trial Results - The international multicenter phase III clinical trial was randomized, double-blind, and placebo-controlled, involving 402 eligible patients from multiple countries [6]. - The primary efficacy endpoint was achieved, with the APL-1702 group showing an 89.4% higher response rate compared to the placebo group (41.1% vs. 21.7%, p = 0.0001) [6]. - The pathological regression rate for the APL-1702 group was significantly higher than that of the placebo group (47.0% vs. 29.5%, p < 0.001) [7]. - APL-1702 demonstrated a 103.90% increase in the clearance rate of high-risk HPV types 16/18 compared to the placebo group (31.4% vs. 15.4%, p = 0.011) [7]. - The overall response rate for the APL-1702 group reached 44.4% at the 12-month follow-up [7]. Group 3: Market Potential and Clinical Need - There is a significant unmet clinical need for non-surgical therapies for cervical precancerous lesions, as current treatments primarily involve invasive cervical excision [5]. - The treatment landscape for cervical precancerous lesions has seen slow progress, with no non-surgical products approved for HSIL based on phase III clinical trial efficacy [5]. - The number of diagnosed HSIL patients in China is expected to reach 1 million by 2030, indicating a growing market potential for APL-1702 [4].

证券代码：688176 证券简称：亚虹医药 公告编号：2025-039 江苏亚虹医药科技股份有限公司 自愿披露关于在 APL-1702 国际多中心Ⅲ期临床试验相 关数据获国际期刊《Med》发表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、近日，江苏亚虹医药科技股份有限公司（以下简称"公司"）产品 APL-1702 用于治疗宫颈高级别鳞状上皮内病变（High-Grade Squamous Intraepithelial Lesion, HSIL）的前瞻、随机、双盲、安慰剂对照的国际多中心Ⅲ期临床试验（以下简 称"本研究"）结果已获 Cell Press 旗下《Med》线上发表。《Med》系由 Cell Press 创立，是继《Cell》《Chem》后，Cell Press 推出的医学领域旗舰刊，属于 Journal Citation Reports（JCR）Q1、中科院双一区的 TOP 期刊。 2、目前上述产品尚处于国家药品监督管理局药品审评中心审评审批阶段， 上述产品能否成功上市及上市时间具有 ...

Core Viewpoint - APL-1702, a product developed by the company for treating High-Grade Squamous Intraepithelial Lesion (HSIL), has had its Phase III clinical trial results published in the prestigious journal "Med" by Cell Press, indicating a significant step in the product's development [1][2] Group 1: Product Information - APL-1702 is a photodynamic therapy product that combines drug and device components, designed as a non-surgical local treatment for HSIL [2] - The product consists of APL-1702 ointment and a device, currently under review by the National Medical Products Administration (NMPA) in China [2] Group 2: Clinical Trial and Publication - The results of the international, multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial for APL-1702 have been published online in "Med," a top-tier journal in the medical field [1] - "Med" is recognized as a flagship journal of Cell Press, following "Cell" and "Chem," and is classified as a Q1 journal in the Journal Citation Reports (JCR) [1] Group 3: Market and Regulatory Considerations - The approval and market launch of APL-1702 remain uncertain as it is still undergoing the review process by the NMPA, with potential commercial success also being uncertain [2] - The publication of the clinical trial data is not expected to have a significant impact on the company's recent performance [2]

Core Viewpoint - The clinical trial results for APL-1702, a treatment for high-grade squamous intraepithelial lesions (HSIL), have been published in the prestigious journal Med, indicating significant efficacy compared to placebo [1] Group 1: Clinical Trial Results - APL-1702 demonstrated an 89.4% increase in response rate compared to the placebo group, with rates of 41.1% for APL-1702 versus 21.7% for placebo (p=0.0001) [1] - The overall response rate at the 12-month mark reached 44.4%, indicating stable long-term efficacy [1] Group 2: Regulatory Status - APL-1702 is currently under review by the National Medical Products Administration (NMPA) in China, with uncertainty regarding its approval and market launch timeline [1] - The publication of the clinical trial data is not expected to have a significant impact on the company's recent performance [1]

Core Points - Yang Mingyuan has resigned from his positions as a director, board secretary, and financial officer of Jiangsu Yahon Pharmaceutical Technology Co., Ltd. due to personal reasons [1][2] - The resignation does not affect the minimum number of board members required by law and will not disrupt the normal operations of the board [1] - The company will promptly appoint a new board secretary and financial officer, with interim responsibilities assigned to the chairman and deputy general manager [1][2] Summary by Sections Resignation Details - Yang Mingyuan submitted his resignation report and will no longer hold any positions within the company after his departure [1] - He directly holds 59,800 shares, approximately 0.01% of the total share capital, and indirectly holds about 682,900 shares through a partnership, representing around 0.12% of the total share capital [2] Impact on the Company - The resignation is in compliance with relevant laws and regulations, ensuring that the board remains functional [1] - Yang Mingyuan has confirmed that there are no unfulfilled public commitments or disagreements with the company [1] Interim Arrangements - PAN KE will temporarily assume the role of board secretary, while ZHUANG CHENGFENG JOHN will take on the responsibilities of the financial officer until new appointments are made [1][3]

Core Points - Yang Mingyuan has resigned from his positions as director, board secretary, and financial officer of Yahuang Pharmaceutical due to personal reasons [2] Summary by Category - **Company Leadership Changes** - Yang Mingyuan submitted his resignation report to the board of directors, indicating his departure from all positions within the company [2]

证券代码：688176 证券简称：亚虹医药 公告编号：2025-038 公司及董事会对于杨明远先生在担任公司董事、董事会秘书、财务负责人期 间为公司发展所做出的重要贡献表示衷心的感谢。 江苏亚虹医药科技股份有限公司 关于公司董事兼高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）董事会于近日收到杨 明远先生的《辞任报告》，因个人原因，杨明远先生申请辞去公司董事、董事会 秘书、财务负责人职务，离任后不再担任公司任何职务。具体情况如下： | 姓名 | 离任职务 | 离任时间 | | | 原定任期到 | 离任 | 是否继续在上 市公司及其控 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 期日 | 原因 | | | | | | | | | | | 股子公司任职 | 公开承诺 | | 杨明远 | 董事、董事 会秘书、财 | 2025 年 30 ...

Core Viewpoint - Yang Mingyuan has resigned from his positions as director, board secretary, and financial officer of Jiangsu Yahuang Pharmaceutical Technology Co., Ltd. for personal reasons, effective September 30, 2025, without affecting the board's normal operation [1] Group 1 - Yang Mingyuan's resignation does not reduce the number of board members below the legal requirement [1] - The company will promptly appoint a new board secretary and financial officer [1] - Until new appointments are made, the chairman and general manager Panke will act as the board secretary, while director and deputy general manager Zhuang Chengfeng John will act as the financial officer [1] Group 2 - Yang Mingyuan holds approximately 0.13% of the company's total share capital and will comply with relevant reduction regulations after his departure [1]

Core Viewpoint - The financial performance and trading activity of Yahuang Pharmaceutical indicate a mixed outlook, with significant revenue growth but ongoing net losses and high financing levels [1][2]. Group 1: Financial Performance - As of June 30, 2025, Yahuang Pharmaceutical reported a revenue of 130 million yuan, representing a year-on-year growth of 61.80% [2]. - The company recorded a net profit attributable to shareholders of -162 million yuan, which is an increase in losses by 11.84% compared to the previous period [2]. Group 2: Shareholder and Trading Activity - As of September 25, 2023, Yahuang Pharmaceutical's stock price decreased by 1.28%, with a trading volume of 66.05 million yuan [1]. - The company had a financing buy-in amount of 3.7364 million yuan and a financing repayment of 6.2467 million yuan on the same day, resulting in a net financing outflow of -2.5103 million yuan [1]. - The total balance of margin trading for Yahuang Pharmaceutical reached 209 million yuan, accounting for 4.45% of its market capitalization, which is above the 80th percentile level over the past year [1]. - The number of shareholders increased by 2.09% to 25,500, while the average circulating shares per person decreased by 2.05% to 14,857 shares [2]. - Among the top ten circulating shareholders, Penghua Medical Technology Stock A ranked as the fourth largest, holding 6.5441 million shares, an increase of 891,300 shares from the previous period [2].

证券代码：688176 证券简称：亚虹医药 公告编号：2025-037 江苏亚虹医药科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 23 日 （二） 股东大会召开的地点：上海市浦东新区高科西路 551 号万信酒店一楼会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 212 | | --- | --- | | 普通股股东人数 | 212 | | 2、出席会议的股东所持有的表决权数量 | 199,925,772 | | 普通股股东所持有表决权数量 | 199,925,772 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 35.5421 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 35.5421 | （四） ...